The Susan G Komen Breast Cancer Fdn Group

“Number of voting members of the governing body this represents the total number of board members that serve on the boards of the affiliates that comprise the komen group return.”

“Executive committee the majority of komen affiliate bylaws (the bylaws) provide for executive committees to be comprised of a minimum of three members including the board president, treasurer and secretary. Most also include the executive director or ceo as an ex officio, non-voting member of the committee. All other members appointed to this committee must be board directors. The bylaws provide that the executive committee has the power to act in place of the board of directors between board meetings on all matters except those specifically reserved to the board by the bylaws or by state law. All actions taken by the executive committee are reported to the board at the next board meeting. This delegation does not relieve the board of any of its responsibilities imposed by law.”

“Decisions of governing body subject to approval by other persons in addition to receiving approval from its board of directors, a komen affiliate must receive the approval of komen parent prior to amending its articles of incorporation/ certificate of formation and bylaws. A komen affiliate is also subject to its affiliation agreement with komen parent and other policies promulgated by komen parent.”

“Describe the process used by management &/or governing body to review 990 as part of the year end financial statement and form 990 preparation process, the management of each affiliate prepares a workbook detailing key information necessary to accurately complete the group form 990. This information is reviewed by the parent organization's management and used to prepare the materials for the form 990 with the assistance of and review by external accountants. Senior levels of the parent organization's management review and comment on the final draft of the form 990, which is then presented to the komen parent audit committee of the board of directors. The audit committee reviews and approves the form 990 prior to filing. The public disclosure copy of the group form 990 is also made available to each affiliate board prior to filing.”

“Description of process to monitor transactions for conflict of interest the organization requires every affiliate board member, committee member, key volunteer, and employee to avoid conflicts of interest. It also requires these persons to report any actual and/or potential conflicts of interest as soon as possible. Additionally, each of these persons is required to complete an annual statement acknowledging the policy and reporting any additional actual/potential conflicts of interest. Any reported conflicts are reviewed by komen affiliate staff and reported to the affiliate's board of directors. Each affiliate board is responsible for reviewing reported actual/potential conflicts of interest and taking any necessary and appropriate action, such as recusal from decisions impacted by the conflict of interest.”

“Offices & positions for which process was used, & year process was begun each komen affiliate is independently responsible for determining the compensation for its chief executive officer, executive director, top management officials, other officers, or key employees of the affiliate. The general process is as follows: the independent members of the board, a committee or designee of the board researches salary ranges for comparable descriptions and accordingly sets the salary to a reasonable and comparable level, taking into consideration factors such as geographic location, skill set, experience, and job requirements. The independent members of the board base their final decision on this information, such decision being made prior to the payment of any compensation.”

“Availability of gov docs, conflict of interest policy, & fin stmts to gen public the organization's audited financial statements and the group form 990 are publicly available at www.komen.org. The articles of incorporation/certification of formation are available in the state in which each affiliate is incorporated, and other governing documents are made available as required by state law. Form 1023 is not online but available to the public upon request.”

“Susan g. Komen's mission is to save lives from breast cancer, by finding breakthroughs to prevent, detect, treat, and cure breast cancer, and by meeting most critical needs in communities to ensure everyone gets the breast cancer care they need when they need it. Komen takes a 360 degree approach to fight breast cancer through . Research, to drive breakthroughs that will bring us new knowledge and advances in care for all, . Community health, to empower people with trustworthy information and support people in their breast health journey through direct services, community programs and health systems change. . And public policy, where we advocate for policies to create systemic and lasting changes that will fund and facilitate research and alleviate the burden on patients and protect access to affordable, high-quality health care for all. Komen is a leading global breast cancer organization, having funded more breast cancer research than any other nonprofit outside of the u.s. Government while providing real time help to those facing the disease. Since its founding in 1982, komen has funded over $1.1 billion in breast cancer research in more than 2700 grants and 500 clinical trials conducted by thousands of the world's best and brightest researchers across the us and around the world. Komen has also provided over $2.3 billion in funding for patient navigation, screening, diagnosis, treatment, education, advocacy, and psychosocial support programs serving millions of people in more than 60 countries worldwide. Komen was founded by nancy g. Brinker, who promised her sister, susan g. Komen, that she would end the disease that claimed suzy's life. With this investment, komen is supporting laboratory research, translational studies, and clinical trials that are paving the road with scientific discoveries that are: - unravelling the biology of breast cancer, - leading to the development of new breast cancer drugs, - development of new technologies and tests, and - new interventions that are changing the standard of breast cancer care and improving the delivery of that care. Our goal is to advance personalized medicine and improve health outcomes for everyone. Komen has had more than 680 research discoveries since we started tracking them in 2016 that are moving us closer to that goal. Nearly two-thirds of these discoveries focus on our research priorities of conquering metastatic and aggressive breast cancers and eliminating breast cancer disparities. They include such things as new biomarkers, new drug targets, new treatments, and new healthcare delivery tools in paving this road with scientific discoveries, we're also paving it with hope. The hope that new ways to detect, diagnose, treat, prevent - and ultimately cure - breast cancer are around the corner. There when people with breast cancer need them to allow them to live longer, with improved quality of life. Research since its founding in 1982, komen's research investments have contributed to many major advances in breast cancer. The progress has been significant - today, we know that breast cancer is more than a single disease. We have a better understanding of the genetics of breast cancer and the critical need to tailor screening, diagnosis, treatment, and prevention strategies to individuals through advances in precision medicine. Komen's research programs are focused on breakthrough research to prevent and cure breast cancer through better approaches for early detection and diagnosis, understanding metastasis and recurrence, and developing novel therapies for all stages of breast cancer, with the goal of supporting work that has significant potential to lead to new treatments and technologies. Komen's research programs are guided by 46 of the world's leaders in breast cancer research, oncology and advocacy. The scientific advisory board assists komen in setting its research strategy and prioritizing its research investment. The komen scholars lead and participate in komen'”

“Patient support fy23 marked the creation of the susan g. Komen patient care center. The overarching goal of our patient care center offerings is to save lives by ensuring patients stay in the breast cancer continuum of care, overcome barriers and challenges to high-quality breast care services, complete treatment, and have a high quality of life and improved long-term outcomes. We serve tens of thousands of individuals nationwide and provide a suite of essential patient services, including one-on-one personal connection to offer psychosocial support; resource navigation to local services; breast health education; connection to clinical trials; and financial assistance to patients in treatment. The patient care center includes the susan g. Komen breast care helpline, the treatment assistance program, and patient navigation. The center served over 17,000 people in fy23. Susan g. Komen is the nonpartisan voice of more than 3.8 million breast cancer survivors, those living with the disease and the people who love them. Komen works to educate people about public policy issues, so they are empowered to become forceful advocates for themselves and their neighbors, and then unites their collective voices for maximum impact. Through our center for public policy, komen ensures that our policymakers are educated about the needs of breast cancer patients and prioritize the issues impacting them. Only through informed government action can we make the broad, systemic and lasting change required. Komen's 2022-2023 public policy and advocacy priorities included: expanding access to affordable, high-quality health care for all patient populations; supporting increased state and federal funding for breast cancer research and increased education, utlization of and access to clinical trials; supporting state and federal funding for the centers for disease control and prevention's (cdc) national breast and cervical cancer early detection program (nbccedp); advocating for state and federal policies to improve insurance coverage of breast cancer treatments, including those that would require oral parity, preclude specialty tiers and prevent step therapy protocols; and advocating for state and federal policies to reduce or eliminate out-of-pocket costs for medically necessary diagnostic imaging. Komen engaged on these priorities across the country, some examples are included below: in arkansas, florida, georgia, iowa, kansas, massachusetts, minnesota, and texas komen worked to introduce legislation that eliminated patient's out-of-pocket costs for medically necessary diagnostic imaging for state regulated health plans. Covered imaging includes diagnostic mammography, breast ultrasound and/or breast mri. Komen worked within numerous coalitions to address insurance barriers to care through legislation in states across the country. This includes an effort in new jersey to limit out-of-pocket costs patients experience for needed treatments and in ohio where legislation was passed to prohibit the use of step therapy protocols for therapies used by stage four cancer patients. Funding and eligibility of state breast and cervical cancer screening programs continued to be a focus for komen. In colorado, our advocates were able to prevent a 33 percent cut for the women's wellness connection, the state screening program. In missouri and oklahoma, we supported coalition efforts to pass ballot initiatives to expand medicaid eligibility in the state. Komen submitted comment letters on proposed state waivers that would place burdensome restrictions on medicaid eligibility. The proposed waivers called for minimum work or community engagement requirements for medicaid recipients. In addition, many of the states included coverage lock-outs for failure to comply. The proposed provisions would have placed unnecessary burdens on women undergoing treatment, ultimately leading to the state's most fragile citizens becoming ineligible for coverage and facing the reality of”

“Additional details on grants for nearly 40 years, susan g. Komen has worked to fulfill its vision of creating a world without breast cancer through its mission of saving lives by meeting the most critical needs in our communities and investing in breakthrough research to better detect, prevent, treat breast cancers. Over the last three years, komen continued to implement a series of changes begun in 2020 to strengthen its financial and operational position in response to the changing needs of the breast cancer community and economic conditions resulting from the covid-19 pandemic. Komen has nearly completed the consolidation of all operations of its independent affiliates into its headquarters organization, resulting in a single organization. This consolidation is enabling komen to leverage the combined expertise of its mission leaders to deliver a united mission program, utilizing technology as a key driver to connect to people who need to access care where they are and to help improve the patient experience, as well as resulted in administrative and operational efficiencies. Central to komen's vision is a steadfast commitment to investing in breakthrough research. Komen remained committed to investing in research focused on its primary focus on metastatic breast cancer and understanding and eliminating disparities in breast cancer outcomes between black and white patients. Despite the economic uncertainty and challenging fundraising environment, komen awarded $40 million in new research awards. While we continue to invest in research into new treatments, komen supports people who are facing breast cancer today through a growing suite of patient care services, including direct financial assistance through its treatment assistance program, eligible to help pay for expenses that may serve as a barrier to attaining the care needed to survive, such as co-pays, transportation, childcare or rent.”